Heart Care in Duchenne: Why Monitoring Starts Early
DMD cardiomyopathy is now the leading cause of death in Duchenne. Early heart monitoring and cardio-protective therapy are core to current standards of care.
Shorter posts on DMD news, policy, and research. Useful context between long-form articles.
DMD cardiomyopathy is now the leading cause of death in Duchenne. Early heart monitoring and cardio-protective therapy are core to current standards of care.
Dmd patient advocacy history shows how families shaped research priorities, drug review, care standards, and access debates.
Health misinformation rare disease debates can distort uncertainty, trust, access, and family decision-making around emerging therapies.
Newborn screening for Duchenne may support earlier care and counseling, but evidence, ethics, and treatment access remain unsettled.
Duchenne treatment access in Georgia: how evidence, cost, protests, and misinformation collided in a rare disease care debate.
Dmd treatment access by country varies through regulators, payers, health technology assessment, pricing, and local budgets.
Dmd transition to adulthood covers adult care, independence, assistive technology, education, work, and identity.
Mental health in Duchenne muscular dystrophy care: patients, parents, siblings, anxiety, depression, behavior, and caregiver strain.
School accommodations for Duchenne can cover access, fatigue, learning, emergency planning, mobility, and inclusion in everyday school life.
Dmd standards of care include coordinated neuromuscular, heart, lung, rehab, bone, nutrition, and psychosocial support.
Use this dmd clinical trial guide to understand phases, endpoints, eligibility, placebo, risks, and questions for a care team.
Understand dmd treatment cost factors, including rare disease economics, manufacturing, evidence uncertainty, and payer decisions.
Gene therapy for Duchenne muscular dystrophy, updated: micro-dystrophin, FDA approval, safety signals, and the unresolved questions ahead.
Exon skipping for Duchenne, explained: who may qualify, why approvals differ across jurisdictions, and why evidence debates continue.
Corticosteroids in Duchenne muscular dystrophy: evidence on benefits, side effects, and the treatment questions families can bring to clinicians.
Understand the dmd diagnosis pathway, from early symptoms and CK testing to genetic confirmation and specialist follow-up.
Early signs of Duchenne muscular dystrophy include delayed walking, frequent falls, calf enlargement, and when to ask a clinician about testing.
A dmd carrier mother may need genetic counseling, family testing, and cardiac follow-up. Learn the questions to raise with clinicians.
This dystrophin gene explained guide covers what dystrophin does, how mutations disrupt muscle, and why results shape DMD care.
Duchenne versus Becker muscular dystrophy in plain English: the shared gene, the different severity, and the diagnosis questions families ask.
What is Duchenne muscular dystrophy? Why it affects muscle, how symptoms appear, and what families can ask their care team next.
Why this site exists, what we publish, and the editorial principles behind it.